Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas

Brain Tumor Pathology

Volumn 32, Issue 2, 2015, Pages 99-104

  Sonoda, Yukihiko ^a   Shibahara, Ichiyoo ^a   Kawaguchi, Tomohiro ^a   Saito, Ryuta ^a   Kanamori, Masayuki ^a   Watanabe, Mika ^b   Suzuki, Hiroyoshi ^c   Kumabe, Toshihiro ^d   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c SENDAI CITY MEDICAL CENTER   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1p19q co deletion; Anaplastic glioma; IDH mutation; Location

Indexed keywords

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN;

BRAIN CORTEX; BRAIN TUMOR; CHROMOSOME 1; GENE DELETION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GLIOMA; HUMAN; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RETROSPECTIVE STUDY;

BRAIN NEOPLASMS; CEREBRAL CORTEX; CHROMOSOMES, HUMAN, PAIR 1; GENE DELETION; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MUTATION; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939966771     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-014-0211-3     Document Type: Article

References (17)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon
2. The committee of Brain Tumor Registry of Japan (2014) Report of brain tumor registry of Japan (2001–2004) 13th edn
3. Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990
4. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722
5. Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
6. Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561
7. Yan H, Bigner DD, Velculescu V et al (2009) Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69:9157–9159
8. Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891
9. Kim JW, Park CK, Park SH et al (2010) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82:224–227
10. Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662–670
11. Qi S, Yu L, Li H et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7:1895–1902
12. Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998
13. Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355
14. Shibahara I, Sonoda Y, Shoji T et al (2014) Malignant clinical features of anaplastic gliomas without IDH mutation. Neuro Oncol. doi:10.1093/neuonc/nou112
15. Persson AI, Petritsch C, Swartling FJ et al (2010) Non-stem cell origin for oligodendroglioma. Cancer Cell 18:669–682
16. Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490
17. Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153